Sugi Predict

Sugi Predict / Compounds / SCHEMBL1359397

SCHEMBL1359397

SCHEMBL1359397

O=S(=O)(c1ccccc1)n1ccc2cc(Br)cnc21

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 1/20 0.61
▸ ENPP3 O14638 4/20 0.57
▸ ENPP1 P22413 3/20 0.57
▸ HTR6 P50406 8/20 0.49
▸ MEN1 O00255 3/20 0.49
▸ KMT2A Q03164 3/20 0.49
▸ HTT P42858 2/20 0.49
▸ ALDH1A1 P00352 1/20 0.49
▸ LMNA P02545 1/20 0.49
▸ HPGD P15428 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ L3MBTL1 Q9Y468 3/20 0.48
▸ PKM P14618 2/20 0.48
▸ MET P08581 1/20 0.43
▸ POLB P06746 1/20 0.43
▸ RAPGEF4 Q8WZA2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13199790 0.90 PKM (0.52) CYP2C19ENPP3ENPP1HTR6MEN1
SCHEMBL18549257 0.89 ENPP3 (0.49) CYP2C19ENPP3ENPP1HTR6MEN1
SCHEMBL17165072 0.86 PKM (0.45) CYP2C19ENPP3ENPP1HTR6MEN1
SCHEMBL1713486 0.86 L3MBTL1 (0.61) CYP2C19ENPP3ENPP1HTR6MEN1
SCHEMBL18549262 0.86 PKM (0.61) CYP2C19ENPP3ENPP1HTR6MEN1
SCHEMBL18549192 0.83 ENPP3 (0.46) CYP2C19ENPP3ENPP1HTR6MEN1
SCHEMBL1958833 0.83 CYP2C19 (0.61) CYP2C19HTR6MEN1KMT2AHTT
SCHEMBL299699 0.83 CYP2C19 (0.61) CYP2C19ENPP3ENPP1HTR6MEN1
SCHEMBL10142546 0.83 CYP2C19 (0.61) CYP2C19HTR6MEN1KMT2AHTT
SCHEMBL18346376 0.83 CYP2C19 (0.61) CYP2C19ENPP3ENPP1HTR6MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250019378-A1 PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS HALIA THERAPEUTICS INC (US) 2025-01-16 — — US disclosed
US-20240425499-A1 TYRO3 INHIBITORS HALIA THERAPEUTICS INC (US) 2024-12-26 — — US disclosed
WO-2023064218-A1 TYRO3 INHIBITORS Halia Therapeutics, Inc. (US) 2023-04-20 — — WO disclosed
WO-2023064218-A1 TYRO3 INHIBITORS Halia Therapeutics, Inc. (US) 2023-04-20 — — WO disclosed
WO-2023049270-A1 PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS Halia Therapeutics, Inc. (US) 2023-03-30 — — WO disclosed
EP-3313530-B1 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF DANA FARBER CANCER INST INC (US) 2022-10-05 — — EP disclosed
CN-112110941-B Compound serving as Hippo signal pathway inhibitor 四川大学 2022-07-12 — — CN disclosed
US-20210315894-A9 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2021-10-14 — — US disclosed
EP-3386980-B1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC (US) 2021-10-13 — — EP disclosed
US-20210253571-A1 AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR WUXI LIFE FOUNTAIN BIOTECH CO., LTD (CN) 2021-08-19 — — US disclosed
EP-2183243-A2 PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS Pfizer Inc. (US) 2010-05-12 — — EP disclosed
US-20090221608-A1 PYRAZOLE COMPOUNDS PFIZER INC. 2009-09-03 — — US disclosed
US-20090221608-A1 PYRAZOLE COMPOUNDS PFIZER INC. 2009-09-03 — — US disclosed
US-20090221608-A1 PYRAZOLE COMPOUNDS PFIZER INC. 2009-09-03 — — US disclosed
CN-101484454-A Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition SOLVAY PHARM B V (NL) 2009-07-15 — — CN disclosed
EP-2041131-A1 AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYLCHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION Solvay Pharmaceuticals B.V. (NL) 2009-04-01 — — EP disclosed
WO-2009016460-A2 PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS PFIZER INC. (US) 2009-02-05 — — WO disclosed
WO-2009016460-A2 PYRAZOLE COMPOUNDS AND THEIR USE AS RAF INHIBITORS PFIZER INC. (US) 2009-02-05 — — WO disclosed
US-20080009514-A1 AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION ABBVIE B.V. (NL) 2008-01-10 — — US disclosed
WO-2008003736-A1 AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYLCHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION SOLVAY PHARMACEUTICALS B.V. (NL) 2008-01-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250019378-A1 PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS TYRO3, TH, TYR CYP2C19 760/4885ENPP3 546/4885ENPP1 970/4885
US-20090221608-A1 PYRAZOLE COMPOUNDS BRAF, RAF1, NRAS CYP2C19 45/4885ENPP3 2496/4885ENPP1 2921/4885
US-20210315894-A9 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF CDK3, CDK1, CDK14 CYP2C19 1194/4885ENPP3 266/4885ENPP1 525/4885
US-20080009514-A1 AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION CHRNA5, CHRNA7, CHRNA2 CYP2C19 662/4885ENPP3 604/4885ENPP1 650/4885
US-20210253571-A1 AZAINDOLE DERIVATIVE AND USE THEREOF AS FGFR AND C-MET INHIBITOR MET, FGFR1, FGFR2 CYP2C19 669/4885ENPP3 4618/4885ENPP1 4530/4885
US-20240425499-A1 TYRO3 INHIBITORS TYRO3, TYR, TH CYP2C19 1418/4885ENPP3 1096/4885ENPP1 1738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.